Physician profile
Jonathan Cheang
NPI 1700083011
$3,464.32
in general payments reported to CMS, 2019-2025
11 companies · $673 in 2025
The $673 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $387 · 2021: $1,000 · 2022: $430 · 2023: $280 · 2024: $507 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,133.34 | 2019-2025 | Trintellix |
| Lundbeck LLC | $773.28 | 2019-2022 | |
| Abbvie INC. | $745.54 | 2021-2025 | |
| Axsome Therapeutics, INC. | $417.69 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $167.34 | 2020-2025 | Rexulti |
| Allergan, INC. | $57.65 | 2020 | |
| Janssen Pharmaceuticals, INC | $56.55 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.39 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $24.12 | 2023 | Latuda |
| Sage Therapeutics, LLC | $21.05 | 2024 | |
| Bausch Health US, LLC | $16.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cheang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.